{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:01:31Z","timestamp":1793073691545,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801199"],"award-info":[{"award-number":["81801199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-020-00973-9","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T18:02:35Z","timestamp":1611079355000},"page":"868-877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Yun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-2491","authenticated-orcid":false,"given":"De-Cai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis Spectrum Disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"9451","key":"10.1007\/s13311-020-00973-9_bib2","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1007\/s13311-020-00973-9_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs."},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"issue":"2","key":"10.1007\/s13311-020-00973-9_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"13","key":"10.1007\/s13311-020-00973-9_bib6","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult Scler"},{"issue":"3","key":"10.1007\/s13311-020-00973-9_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology."},{"issue":"Suppl 4","key":"10.1007\/s13311-020-00973-9_bib8","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.1007\/s10072-004-0342-0","article-title":"Devic's neuromyelitis optica: clinical features and prognostic factors","volume":"25","author":"Bergamaschi","year":"2004","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1007\/s13311-020-00973-9_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/25785826.2018.1531190","article-title":"Blood-brain barrier dysfunction in immuno-mediated neurological diseases","volume":"41","author":"Shimizu","year":"2018","journal-title":"Immunol Med"},{"issue":"8","key":"10.1007\/s13311-020-00973-9_bib10","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","article-title":"Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption","volume":"23","author":"Uchida","year":"2017","journal-title":"Mult Scler"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1155\/2006\/709869","article-title":"Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis","volume":"22","author":"Waubant","year":"2006","journal-title":"Dis Markers"},{"issue":"2","key":"10.1007\/s13311-020-00973-9_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00973-9_bib13","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis)","volume":"107","author":"Kaiser","year":"2009","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1007\/s13311-020-00973-9_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1021\/acschemneuro.6b00056","article-title":"In Vivo Imaging of Human Neuroinflammation","volume":"7","author":"Albrecht","year":"2016","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1007\/s13311-020-00973-9_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1148\/radiology.169.1.3420246","article-title":"Multiple sclerosis: serial study of gadolinium-enhanced MR imaging","volume":"169","author":"Grossman","year":"1988","journal-title":"Radiology."},{"issue":"5","key":"10.1007\/s13311-020-00973-9_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ana.410340507","article-title":"Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis","volume":"34","author":"Katz","year":"1993","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-020-00973-9_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology."},{"issue":"1","key":"10.1007\/s13311-020-00973-9_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ane.12354","article-title":"Spinal cord ring enhancement in patients with neuromyelitis optica","volume":"132","author":"Yokote","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"10.1007\/s13311-020-00973-9_bib21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-017-1682-1","article-title":"Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/01.WNL.0000046587.83503.1E","article-title":"MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals","volume":"60","author":"Cotton","year":"2003","journal-title":"Neurology."},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/147323001204000427","article-title":"Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability","volume":"40","author":"Tomizawa","year":"2012","journal-title":"J Int Med Res"},{"issue":"1-2","key":"10.1007\/s13311-020-00973-9_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.04.009","article-title":"Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier","volume":"236","author":"Hosokawa","year":"2011","journal-title":"J Neuroimmunol"},{"issue":"Pt 9","key":"10.1007\/s13311-020-00973-9_bib26","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1093\/brain\/awv203","article-title":"Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis","volume":"138","author":"Cramer","year":"2015","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00973-9_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-020-00973-9_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jns.2016.06.030","article-title":"Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder","volume":"368","author":"Seok","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-020-00973-9_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00973-9_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt","year":"2019","journal-title":"J Clin Apher"},{"issue":"12","key":"10.1007\/s13311-020-00973-9_bib32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of Neuromyelitis Optica: Review and Recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1007\/s13311-020-00973-9_bib34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1007\/s13311-020-00973-9_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neurad.2008.12.008","article-title":"MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis","volume":"36","author":"Cassinotto","year":"2009","journal-title":"J Neuroradiol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00973-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:11Z","timestamp":1761807671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011364"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00973-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-41052\/v1","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00973-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}